Search Articles
WILMINGTON, Del. – Directors of Theraclone are not giving shareholders sufficient information to determine whether a proposed merger with PharmAthene Sciences is fair, investors say in a direct and derivative complaint in Chancery Court.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.